coagulation factor VIII associated 1Genealiases: DXS522E · F8A · HAP40
Q-omics provides the consensus-scored F8A1 profile across patient tissues and cancer cell-line models. F8A1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, F8A1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, F8A1 RNA expression shows 9,334 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, HNSC, and TGCT as cancer lineages where F8A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F8A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F8A1 survival associations across molecular data types. F8A1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F8A1 RNA expression–survival associations across cancer types. High F8A1 expression shows unfavorable associations in MESO, COAD and LIHC, but favorable associations in CESC, UVM and ESCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for F8A1 RNA expression.
This table summarizes F8A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for F8A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F8A1 shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, LUAD, BLCA and LUSC. The HNSC box plot shows higher F8A1 RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with F8A1 in patient tissues and cancer cell lines. In patient samples, F8A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, F8A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
